MiMedx Group has been granted a patent for a method of treating cardiac conditions using modified placental tissue. The method involves placing a composition of modified placental tissue near the injured or diseased cardiac tissue to promote healing, without obstructing its function. The modified placental tissue includes a chorion and an amnion, with the composition being in the form of a patch, injectable form, or micronized. GlobalData’s report on MiMedx Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MiMedx Group, cardiothoracic surgery instruments was a key innovation area identified from patents. MiMedx Group's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating cardiac conditions using modified placental tissue
A recently granted patent (Publication Number: US11648281B2) describes a method for treating injured or diseased cardiac tissue using a composition comprising modified placental tissue. The method involves placing the composition near the affected cardiac tissue without obstructing its function. The modified placental tissue includes a chorion and an amnion, with the amnion having an epithelial cell layer and/or a fibroblast layer. The composition can be in the form of a patch, injectable form, or micronized.
The patent claims that the method can be used to treat various cardiac conditions, including ischemia, acute myocardial infarction, cardiomyopathy, unstable angina, heart failure, and more. The composition may also contain stem cell recruiting factors, growth factors, and angiogenesis inducing factors to enhance the treatment.
The composition can form a localized mass, allowing for the retention of the composition near the injured or diseased cardiac tissue. It can also be in sustained or continuous release form. Additionally, the composition may include an extract of placental tissue.
The modified placental tissue can be laminated together, and it can be placed subcutaneously or within approximately 3 cm of the affected cardiac tissue. Alternatively, the placental tissue can be placed on or in the injured or diseased cardiac tissue.
The patent also describes a method for treating a cardiac condition in a patient by administering the composition to an area near the cardiac tissue. This method can be used for treating inflammatory heart conditions or necrotizing heart conditions.
Overall, this patent provides a method for treating injured or diseased cardiac tissue using a composition comprising modified placental tissue. The method offers potential benefits for various cardiac conditions and includes the use of additional factors to enhance treatment. The composition can be delivered in different forms and can be localized near the affected tissue.
To know more about GlobalData’s detailed insights on MiMedx Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
